Accordingly, we conclude that low levels of anti-GAPDH1–22 antibodies, together with low IL-17A levels, are two valid immunological biomarkers of poor prognosis in listeriosis patients with tumors under chemotherapeutic treatment. The gene discussed is IL17A; the disease is listeriosis.